Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

Current challenges in the development of new treatments for lupus.

Dall'Era M, Bruce IN, Gordon C, Manzi S, McCaffrey J, Lipsky PE.

Ann Rheum Dis. 2019 Jan 12. pii: annrheumdis-2018-214530. doi: 10.1136/annrheumdis-2018-214530. [Epub ahead of print]

PMID:
30636212
2.

Anticoagulation in patients with concomitant lupus nephritis and thrombotic microangiopathy: a multicentre cohort study.

Sciascia S, Yazdany J, Dall'Era M, Fenoglio R, Radin M, Aggarwal I, Cuadrado MJ, Schreiber K, Barreca A, Papotti M, Roccatello D.

Ann Rheum Dis. 2018 Dec 14. pii: annrheumdis-2018-214559. doi: 10.1136/annrheumdis-2018-214559. [Epub ahead of print] No abstract available.

PMID:
30552172
3.

Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer.

Liu C, Lou W, Yang JC, Liu L, Armstrong CM, Lombard AP, Zhao R, Noel ODV, Tepper CG, Chen HW, Dall'Era M, Evans CP, Gao AC.

Nat Commun. 2018 Nov 16;9(1):4700. doi: 10.1038/s41467-018-07178-x.

4.

Multiparametric MRI: an important tool to improve risk stratification for active surveillance in prostate cancer.

Chandrasekar T, Dall'Era MA, Tilki D.

BJU Int. 2018 Nov;122(5):721-722. doi: 10.1111/bju.14494. No abstract available.

PMID:
30358932
5.

Psychometric evaluation of the NIH Patient-Reported Outcomes Measurement Information System (PROMIS® ) in a multi-racial, multi-ethnic systemic lupus erythematosus (SLE) cohort.

Katz P, Yazdany J, Trupin L, Rush S, Helmick CG, Murphy LB, Lanata C, Criswell LA, Dall'Era M.

Arthritis Care Res (Hoboken). 2018 Oct 24. doi: 10.1002/acr.23797. [Epub ahead of print]

PMID:
30354017
6.

Adoptive Regulatory T Cell Therapy in a Patient with Systemic Lupus Erythematosus.

Dall'Era M, Pauli ML, Remedios K, Taravati K, Sandoval PM, Putnam AL, Lares A, Haemel A, Tang Q, Hellerstein M, Fitch M, McNamara J, Welch B, Bluestone JA, Wofsy D, Rosenblum MD; Autoimmunity Centers of Excellence.

Arthritis Rheumatol. 2018 Oct 1. doi: 10.1002/art.40737. [Epub ahead of print]

PMID:
30277008
7.

Establishing Surrogate Kidney Endpoints for Lupus Nephritis Clinical Trials: Development and Validation of a Novel Approach to Predict Future Kidney Outcomes.

Mackay M, Dall'Era M, Fishbein J, Kalunian K, Lesser M, Sanchez Guerrero J, Levy DM, Silverman E, Petri M, Arriens C, Lewis EJ, Korbet SM, Conti F, Tesar V, Hruskova Z, Borba EF, Bonfa E, Chan TM, Rathi M, Gupta KL, Jha V, Hasni S, West MR, Silverman E, Solomons N, Houssiau FA, Romera Diaz J, Mejia-Vilet J, Rovin BH.

Arthritis Rheumatol. 2018 Sep 17. doi: 10.1002/art.40724. [Epub ahead of print]

PMID:
30225865
8.

Divergent Biological Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer.

Seiler R, Gibb EA, Wang NQ, Oo HZ, Lam HM, van Kessel KE, Voskuilen CS, Winters B, Erho N, Takhar MM, Douglas J, Vakar-Lopez F, Crabb SJ, van Rhijn BWG, Fransen van de Putte EE, Zwarthoff EC, Thalmann GN, Davicioni E, Boormans JL, Dall'Era M, van der Heijden MS, Wright JL, Black PC.

Clin Cancer Res. 2018 Sep 17. doi: 10.1158/1078-0432.CCR-18-1106. [Epub ahead of print]

PMID:
30224344
9.

New Insights into Ejaculatory Frequency and Prostate Cancer Risk: Association, Causation, or What Do We Have to Lose?

Dall'Era MA, De Vere White RW.

Eur Urol. 2018 Nov;74(5):549-550. doi: 10.1016/j.eururo.2018.08.014. Epub 2018 Sep 1. No abstract available.

PMID:
30177292
10.

Peripheral Blood B Cell Depletion after Rituximab and Complete Response in Lupus Nephritis.

Gomez Mendez LM, Cascino MD, Garg J, Katsumoto TR, Brakeman P, Dall'Era M, Looney RJ, Rovin B, Dragone L, Brunetta P.

Clin J Am Soc Nephrol. 2018 Oct 8;13(10):1502-1509. doi: 10.2215/CJN.01070118. Epub 2018 Aug 8.

PMID:
30089664
11.

Editorial Comment.

Dall'Era M, Lara PN Jr.

J Urol. 2018 Nov;200(5):1003. doi: 10.1016/j.juro.2018.06.071. Epub 2018 Jul 19. No abstract available.

PMID:
30030973
12.

Reply to Radiation therapy does not increase survival in addition to standard androgen deprivation therapy for metastatic prostate cancer: An old, faded picture?

Dall'Era MA, Lo MJ, Chen JY, Cress R, Hamilton AS.

Cancer. 2018 Sep 1;124(17):3619-3620. doi: 10.1002/cncr.31625. Epub 2018 Jul 5. No abstract available.

PMID:
29975411
13.

Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomy.

Vasdev N, Zargar H, Noël JP, Veeratterapillay R, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Gandhi NM, Griffin J, Montgomery JS, Yu EY, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Shariat SF, Wright JL, Morgan TM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Holzbeierlein JM, Thorpe A, Black PC.

World J Urol. 2018 Jun 7. doi: 10.1007/s00345-018-2361-0. [Epub ahead of print]

PMID:
29882105
14.

Changing Incidence of Metastatic Prostate Cancer by Race and Age, 1988-2015.

Dall'Era MA, deVere-White R, Rodriguez D, Cress R.

Eur Urol Focus. 2018 May 4. pii: S2405-4569(18)30106-8. doi: 10.1016/j.euf.2018.04.016. [Epub ahead of print]

PMID:
29735368
15.

Indications for and transitioning to secondary treatment while on active surveillance for prostate cancer.

Glass AS, Dall'Era MA.

Transl Androl Urol. 2018 Apr;7(2):236-242. doi: 10.21037/tau.2018.02.08. Review.

16.

Active surveillance for prostate cancer.

Dall'Era MA, Davies BJ, Eggener S.

Transl Androl Urol. 2018 Apr;7(2):195-196. doi: 10.21037/tau.2018.03.03. No abstract available.

17.

Lupus community panel proposals for optimising clinical trials: 2018.

Merrill JT, Manzi S, Aranow C, Askenase A, Bruce I, Chakravarty E, Chong B, Costenbader K, Dall'Era M, Ginzler E, Hanrahan L, Kalunian K, Merola J, Raymond S, Rovin B, Saxena A, Werth VP.

Lupus Sci Med. 2018 Mar 23;5(1):e000258. doi: 10.1136/lupus-2018-000258. eCollection 2018. Review. Erratum in: Lupus Sci Med. 2018 Jun 11;5(1):e000258corr1.

18.

Nine-year prostate cancer survival differences between aggressive versus conservative therapy in men with advanced and metastatic prostate cancer.

Dall'Era MA, Lo MJ, Chen J, Cress R, Hamilton AS.

Cancer. 2018 May 1;124(9):1921-1928. doi: 10.1002/cncr.31285. Epub 2018 Mar 2.

PMID:
29499075
19.

A contemporary population-based study of testicular sex cord stromal tumours: Presentation, treatment patterns, and predictors of outcome.

Yuh LM, Lara PN Jr, Wagenaar RM, Evans CP, Dall'era MA, Cress R, Yap SA.

Can Urol Assoc J. 2017 Sep;11(9):E344-E349. doi: 10.5489/cuaj.4402.

20.

Genomic Markers in Prostate Cancer Decision Making.

Cucchiara V, Cooperberg MR, Dall'Era M, Lin DW, Montorsi F, Schalken JA, Evans CP.

Eur Urol. 2018 Apr;73(4):572-582. doi: 10.1016/j.eururo.2017.10.036. Epub 2017 Nov 10. Review.

PMID:
29129398
21.

Microchamber Cultures of Bladder Cancer: A Platform for Characterizing Drug Responsiveness and Resistance in PDX and Primary Cancer Cells.

Gheibi P, Zeng S, Son KJ, Vu T, Ma AH, Dall'Era MA, Yap SA, de Vere White RW, Pan CX, Revzin A.

Sci Rep. 2017 Sep 25;7(1):12277. doi: 10.1038/s41598-017-12543-9.

22.

The Incidence and Prevalence of Systemic Lupus Erythematosus in San Francisco County, California: The California Lupus Surveillance Project.

Dall'Era M, Cisternas MG, Snipes K, Herrinton LJ, Gordon C, Helmick CG.

Arthritis Rheumatol. 2017 Oct;69(10):1996-2005. doi: 10.1002/art.40191. Epub 2017 Sep 10.

23.

Utility of Anterior Zone Biopsy in Men Enrolled in Active Surveillance for Prostate Cancer.

Glass AS, Pugashetti NB, Dall'Era MA, Evans CP, Yap SA.

Clin Genitourin Cancer. 2017 Jul 14. pii: S1558-7673(17)30204-5. doi: 10.1016/j.clgc.2017.07.007. [Epub ahead of print]

PMID:
28789835
24.

Editorial Comment.

Dall'Era M.

J Urol. 2017 Aug;198(2):328. doi: 10.1016/j.juro.2017.02.3373. Epub 2017 May 12. No abstract available.

PMID:
28506736
25.

Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy.

Seiler R, Ashab HAD, Erho N, van Rhijn BWG, Winters B, Douglas J, Van Kessel KE, Fransen van de Putte EE, Sommerlad M, Wang NQ, Choeurng V, Gibb EA, Palmer-Aronsten B, Lam LL, Buerki C, Davicioni E, Sjödahl G, Kardos J, Hoadley KA, Lerner SP, McConkey DJ, Choi W, Kim WY, Kiss B, Thalmann GN, Todenhöfer T, Crabb SJ, North S, Zwarthoff EC, Boormans JL, Wright J, Dall'Era M, van der Heijden MS, Black PC.

Eur Urol. 2017 Oct;72(4):544-554. doi: 10.1016/j.eururo.2017.03.030. Epub 2017 Apr 5.

PMID:
28390739
26.

Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence.

Sciascia S, Radin M, Yazdany J, Tektonidou M, Cecchi I, Roccatello D, Dall'Era M.

Rheumatol Int. 2017 Aug;37(8):1249-1255. doi: 10.1007/s00296-017-3686-5. Epub 2017 Mar 3. Review.

PMID:
28258475
27.

Treatment of lupus nephritis: current paradigms and emerging strategies.

Dall'Era M.

Curr Opin Rheumatol. 2017 May;29(3):241-247. doi: 10.1097/BOR.0000000000000381. Review.

PMID:
28207493
28.

Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: A systematic review.

Sciascia S, Radin M, Yazdany J, Levy RA, Roccatello D, Dall'Era M, Cuadrado MJ.

Autoimmun Rev. 2017 Mar;16(3):287-293. doi: 10.1016/j.autrev.2017.01.010. Epub 2017 Jan 29. Review.

29.

Effect of Neoadjuvant Chemotherapy on Renal Function following Radical Cystectomy: Is there a Meaningful Impact?

Chandrasekar T, Pugashetti N, Durbin-Johnson B, Dall'Era MA, Evans CP, deVere White RW, Yap SA.

Bladder Cancer. 2016 Oct 27;2(4):441-448. doi: 10.3233/BLC-160071.

30.

Active surveillance for intermediate-risk prostate cancer.

Dall'Era MA, Klotz L.

Prostate Cancer Prostatic Dis. 2017 Mar;20(1):1-6. doi: 10.1038/pcan.2016.51. Epub 2016 Nov 1. Review.

31.

Genomic and Biological Markers to Select Treatment for Patients with Prostate Cancer: Choose Wisely, My Friend.

Dall'Era M, Evans C.

J Urol. 2017 Jan;197(1):8-9. doi: 10.1016/j.juro.2016.10.048. Epub 2016 Oct 13. No abstract available.

PMID:
27746279
32.

Disulfide-crosslinked nanomicelles confer cancer-specific drug delivery and improve efficacy of paclitaxel in bladder cancer.

Pan A, Zhang H, Li Y, Lin TY, Wang F, Lee J, Cheng M, Dall'Era M, Li T, deVere White R, Pan CX, Lam KS.

Nanotechnology. 2016 Oct 21;27(42):425103. doi: 10.1088/0957-4484/27/42/425103. Epub 2016 Sep 19.

33.

Blood-Borne RNA Correlates with Disease Activity and IFN-Stimulated Gene Expression in Systemic Lupus Erythematosus.

Doedens JR, Jones WD, Hill K, Mason MJ, Gersuk VH, Mease PJ, Dall'Era M, Aranow C, Martin RW, Cohen SB, Fleischmann RM, Kivitz AJ, Burge DJ, Chaussabel D, Elkon KB, Posada JA.

J Immunol. 2016 Oct 1;197(7):2854-63. doi: 10.4049/jimmunol.1601142. Epub 2016 Aug 17.

34.

Reasons for Abandonment of Active Surveillance in Men with Prostate Cancer.

Dall'Era MA.

J Urol. 2016 Sep;196(3):637-8. doi: 10.1016/j.juro.2016.06.078. Epub 2016 Jun 15. No abstract available.

PMID:
27316451
35.

Evolving patterns of care in the management of stage I non-seminomatous germ cell tumors: data from the California Cancer Registry.

Yap SA, Yuh LM, Evans CP, Dall'Era MA, Wagenaar RM, Cress R, Lara PN Jr.

World J Urol. 2017 Feb;35(2):277-283. doi: 10.1007/s00345-016-1870-y. Epub 2016 Jun 15.

PMID:
27306686
36.

Mapping Perceptions of Lupus Medication Decision-Making Facilitators: The Importance of Patient Context.

Qu H, Shewchuk RM, Alarcón G, Fraenkel L, Leong A, Dall'Era M, Yazdany J, Singh JA.

Arthritis Care Res (Hoboken). 2016 Dec;68(12):1787-1794. doi: 10.1002/acr.22904.

37.

A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer.

Chow H, Ghosh PM, deVere White R, Evans CP, Dall'Era MA, Yap SA, Li Y, Beckett LA, Lara PN Jr, Pan CX.

Cancer. 2016 Jun 15;122(12):1897-904. doi: 10.1002/cncr.29927. Epub 2016 Mar 28.

38.

Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA.

Collins CE, Dall'Era M, Kan H, Macahilig C, Molta C, Koscielny V, Chang DJ.

Lupus Sci Med. 2016 Jan 11;3(1):e000118. doi: 10.1136/lupus-2015-000118. eCollection 2016.

39.

A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial.

Tamirou F, Lauwerys BR, Dall'Era M, Mackay M, Rovin B, Cervera R, Houssiau FA; MAINTAIN Nephritis Trial Investigators.

Lupus Sci Med. 2015 Nov 12;2(1):e000123. doi: 10.1136/lupus-2015-000123. eCollection 2015.

40.

Clinical Case Discussion: Intermediate-risk Prostate Cancer: The Case for Active Surveillance.

Dall'Era MA, Davies BJ.

Eur Urol Focus. 2015 Sep;1(2):208-209. doi: 10.1016/j.euf.2015.07.001. Epub 2015 Jul 15.

PMID:
28723436
41.

DGCR8 is essential for tumor progression following PTEN loss in the prostate.

Belair CD, Paikari A, Moltzahn F, Shenoy A, Yau C, Dall'Era M, Simko J, Benz C, Blelloch R.

EMBO Rep. 2015 Sep;16(9):1219-32. doi: 10.15252/embr.201439925. Epub 2015 Jul 23.

42.

Barriers to Medication Decision Making in Women with Lupus Nephritis: A Formative Study using Nominal Group Technique.

Singh JA, Qu H, Yazdany J, Chatham W, Dall'era M, Shewchuk RM.

J Rheumatol. 2015 Sep;42(9):1616-23. doi: 10.3899/jrheum.150168. Epub 2015 Jul 15.

PMID:
26178276
43.

Metastatic signet-ring cell carcinoma of the urinary bladder: A novel management approach to a rare tumour.

Pugashetti N, Yap SA, Lara PN Jr, Gandour-Edwards R, Dall'Era MA.

Can Urol Assoc J. 2015 Mar-Apr;9(3-4):E204-7. doi: 10.5489/cuaj.2447.

44.

What is the Optimal Way to Select Candidates for Active Surveillance of Prostate Cancer?

Dall'Era M, Carroll P.

J Urol. 2015 Sep;194(3):615-6. doi: 10.1016/j.juro.2015.06.069. Epub 2015 Jun 14. No abstract available.

PMID:
26079332
45.

Identification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome.

Dall'Era M, Levesque V, Solomons N, Truman M, Wofsy D.

Lupus Sci Med. 2015 May 20;2(1):e000089. doi: 10.1136/lupus-2015-000089. eCollection 2015.

46.

Nanotechnology in bladder cancer: current state of development and clinical practice.

Tomlinson B, Lin TY, Dall'Era M, Pan CX.

Nanomedicine (Lond). 2015;10(7):1189-201. doi: 10.2217/nnm.14.212. Review.

47.

Cardiopulmonary Bypass has No Significant Impact on Survival in Patients Undergoing Nephrectomy and Level III-IV Inferior Vena Cava Thrombectomy: Multi-Institutional Analysis.

Nguyen HG, Tilki D, Dall'Era MA, Durbin-Johnson B, Carballido JA, Chandrasekar T, Chromecki T, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Espinós EL, Mandel P, Martinez-Salamanca JI, Master VA, McKiernan JM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Rodriguez-Faba O, Russo P, Scherr DS, Shariat SF, Spahn M, Terrone C, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA, Evans CP.

J Urol. 2015 Aug;194(2):304-308. doi: 10.1016/j.juro.2015.02.2948. Epub 2015 Mar 19.

48.

Randomized, Double-Blind, Placebo-Controlled Trial of the Effect of Vitamin D3 on the Interferon Signature in Patients With Systemic Lupus Erythematosus.

Aranow C, Kamen DL, Dall'Era M, Massarotti EM, Mackay MC, Koumpouras F, Coca A, Chatham WW, Clowse ME, Criscione-Schreiber LG, Callahan S, Goldmuntz EA, Keyes-Elstein L, Oswald M, Gregersen PK, Diamond B.

Arthritis Rheumatol. 2015 Jul;67(7):1848-57. doi: 10.1002/art.39108.

49.

Patient and disease factors affecting the choice and adherence to active surveillance.

Dall'Era MA.

Curr Opin Urol. 2015 May;25(3):272-6. doi: 10.1097/MOU.0000000000000154. Review.

PMID:
25692724
50.

Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort.

Dall'Era M, Cisternas MG, Smilek DE, Straub L, Houssiau FA, Cervera R, Rovin BH, Mackay M.

Arthritis Rheumatol. 2015 May;67(5):1305-13. doi: 10.1002/art.39026.

Supplemental Content

Loading ...
Support Center